Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650413 | 0.82 | KCNH2 (0.51) | HDAC1HDAC2HDAC3 | |
| SCHEMBL653107 | 0.82 | KCNH2 (0.49) | MAPTALDH1A1IKBKBHDAC1ACMSD | |
| SCHEMBL1690753 | 0.82 | ESR2 (0.45) | KMT2AMEN1RXRARXRBDHODH | |
| SCHEMBL247809 | 0.80 | KDM4E (0.38) | MAPTKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL1512084 | 0.78 | KEAP1 (0.42) | MAPTKDM4EALDH1A1GAAHTT | |
| SCHEMBL22637598 | 0.75 | GAA (0.37) | MAPTKDM4EALDH1A1GAA | |
| SCHEMBL13811467 | 0.74 | BRD4 (0.41) | MAPTKDM4EKMT2AMEN1USP2 | |
| SCHEMBL1648158 | 0.74 | ALAD (0.37) | ALDH1A1LMNAHDAC2RXRARXRB | |
| SCHEMBL3790820 | 0.73 | KMT2A (0.52) | MAPTKDM4EKMT2AMEN1USP2 | |
| SCHEMBL1932590 | 0.73 | HTR6 (0.48) | MAPTKDM4EKMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-05-19 | — | — | US | disclosed |
| US-8158825-B2 | Modified malonate derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110130361-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | GRIMM JONATHAN | 2011-06-02 | — | — | US | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | MAPT 1986/4885KDM4E 399/4885KMT2A 185/4885 |
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | GATAD2B, GATAD2A, HDAC2 | MAPT 636/4885KDM4E 635/4885KMT2A 62/4885 |
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | MAPT 1952/4885KDM4E 1428/4885KMT2A 258/4885 |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | SIRT1, NQO1, TXNRD2 | MAPT 1091/4885KDM4E 284/4885KMT2A 121/4885 |
| US-20110130361-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC2 | MAPT 826/4885KDM4E 250/4885KMT2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.